Specialties

Featured Suppliers

Gold Anchor Naslund Medical

RTI Electronics

Accuray

ProStrakan

Ipsen

Terumo Medical Corporation

January

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

ACI's 2nd Annual Planning, Building, and Operating Successful Proton Therapy Centers

Wed, 2012-02-22

European Congress of Radiology – ECR 2012

Thu, 2012-03-01

The 8th European Breast Cancer Conference (EBCC-8)

Wed, 2012-03-21

Latest Testimonial

‘ECCO – the European CanCer Organisation represents and serves the interests of over 50,000 professionals in oncology through...

Communication & Marketing Manager

Catherine Shiels, Executive MBA

Statins tied to lower risk of fatal prostate cancer Combination therapy useful for advanced hepatoma BiTE antibody shows promise to treat diffuse large B-cell lymphoma Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed Yoga helps breast cancer survivors with fatigue 'Wait-and-see' OK if rectal CA responds completely to chemoradiation Phase III BTOG2 trial assesses combination therapies for advanced lung cancer Vatalanib ineffective against malignant mesothelioma Tivozanib superior to sorafenib in phase III study Recruitment begins in phase III BEACON study

Touch Oncology

Immune Thrombocytopenia
Head and Neck Cancer
Mediastinal Staging
Pharmacologic Symptomatic Treatment

Immune Thrombocytopenia

The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia

Roberto Stasi, Elizabeth Rhodes, Reuben Benjamin, Hubertus Buyck, Fenella Willis, Muriel S Shannon, Edward C Gordon-Smith

European Oncology & Haematology, 2011;7(1):63-70

Head and Neck Cancer

Cetuximab in the Treatment of Locally Advanced Head and Neck Cancer

Rainald Knecht

European Oncology & Haematology, 2011;7(1):16-23

Mediastinal Staging

The Challenge of Mediastinal Staging

Loris Ceron, Lucio Michieletto, Andrea Zamperlin, Laura Mancino

European Oncology & Haematology, 2011;7(1):31-35

Pharmacologic Symptomatic Treatment

Breakthrough Pain in Cancer Patients— Pharmacologic Symptomatic Treatment

Marco Pappagallo

US Oncology & Hematology, 2011;7(1):17-21

Latest News

Lab-made Tissue Superior to Petri Dish Cultures in Cancer Research

13 January 2012

Anti-Cancer Activity Agents Identified Through Drug Screening

6 January 2012

Editor's choice

Treatment of Nausea and Vomiting During Chemotherapy

Karen M Mustian, PhD et al.

Oncology & Hematology Review, 2011;7(2):91-97

Also in Editor's Choice

Treating Endometrial Adenocarcinoma— Do Data Support the Use of Pegylated Liposomal Doxorubicin?

Improving the Outcome of Patients with Castration-resistant Prostate Cancer Through Rational Targeting of the Androgen Receptor

Human Papillomavirus Vaccines and the Prevention of Cervical Cancer— The Dawn of a New Era?

Current and Future Alternatives for Allogeneic Blood Product Transfusions

Tracking versus Gating in the Treatment of Moving Targets

Comparative Efficacy of Reduced or Standard Doses of Lenograstim for Peripheral Blood Stem Cell Mobilisation and Transplantation – A Review

Latest Articles

Current Epidemiology and Prevention of Infectious Complications in Cancer Patients

Corrado Girmenia, Francesco Menichetti

Update on the Management of Febrile Neutropenia

Shiva K Natarajan, Shruthi Narayan, John A Liu Yin

Review of Data for Monoclonal Antibody-purified Plasma-derived Factor IX

Massimo Morfini, Wolfhart Kreuz

Management of Metastatic Castration-resistant Prostate Cancer

Emmanuel S Antonarakis

The Role of Imaging in Suspected Prostate Cancer

Adil Ouzzane, Arnauld Villers

Out Now

European Oncology & Haematology Volume 7 Issue 4

In Partnership

Press Release